Pfizer’s Lipitor Patent Claims Rejected by PTO In Initial Reexamination
Executive Summary
Pfizer may lose patent protection for its blockbuster cholesterol drug Lipitor (atorvastatin) if the U.S. Patent and Trademark Office stands by an initial decision to reject the claims in the basic patent on the drug